Thursday, July 07, 2022 3:08:44 PM
The market thinks HGEN is the same as CYDY or RLFTF. They view all smallcap bio as greasy. They see the Sept 9th EUA decline but don't know the data so they don't understand how close lenzilumab was to getting the EUA.
The primary endpoint population of the BET-B trial had 7.5% lenz mortality and 17.3% placebo mortality in the LIVE-AIR trial. No therapeutic comes close to that efficacy. And it isn't datamining. That subgroup represents well over 50% of patients of the LIVE-AIR trial and it makes sense that earlier treatment would be more effective than later treatment since GM-CSF is upstream. GM-CSF is the master controller. GM-CSF is the cytokine that begins the cytokine storm by beckoning other cytokines. Once the cytokine storm is on full blast, it is too late.
https://www.bbc.com/news/health-56352128
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM